Sort
10,766 grants matching “checkpoint inhibitor”
IGF::OT::IGF SBIR PHASE I TOPIC 354- A NON-INVASIVE APPROACH TO ASSESS MUTATION LOAD IN TUMORS FOR TREATMENT WITH CHECKPOINT INHIBITORS
$222,994Theresa Zhang · Personal Genome Diagnostics, Inc. · N43 · FY2016 · CA
Project 1: Targeting Metastatic Prostate Cancer Patients with Biallelic Loss of CDK12
$222,878Arul M Chinnaiyan · University Of Michigan At Ann Arbor · P50 · FY2021 · CA
PROTEASES AND CHEMOTHERAPY INDUCED APOPTOSIS
$222,856Mayo Clinic Coll Of Medicine, Rochester · R01 · FY2000 · CA
Project 4-Monika Rak
$222,838Monika Rak · Lsu Health Sciences Center · P20 · FY2025 · GM
Dissecting drug resistance in serial uveal melanoma biopsies using integrated, multi-modal single-cell profiling and novel machine learning tools.
$222,661Benjamin Izar · Columbia University Health Sciences · R21 · FY2022 · CA
Project 1: Elucidating the role of AAA ATPase TRIP13 in prostate cancer
$222,657Rajesh Singh · Morehouse School Of Medicine · U54 · FY2022 · CA
Project 1: Elucidating the role of AAA ATPase TRIP13 in prostate cancer
$222,656Rajesh Singh · Morehouse School Of Medicine · U54 · FY2023 · CA
A novel oncolytic virus for pancreatic cancer immunotherapy
$222,440Omeed Moaven · Lsu Health Sciences Center · P20 · FY2025 · GM
Rapid evaluation of immunotherapy regimens in ex vivo human pancreatic tumor slice cultures.
$222,297Hidayatullah G Munshi · Northwestern University At Chicago · R21 · FY2021 · CA
Topoisomerase I Inhibitors in Leukemia and Solid Tumors
$222,233Mayo Clinic Coll Of Medicine, Rochester · R01 · FY2001 · CA
Topoisomerase I Inhibitors in Leukemia and Solid Tumors
$222,233Mayo Clinic · R01 · FY2004 · CA
Topoisomerase I Inhibitors in Leukemia and Solid Tumors
$222,233Mayo Clinic Coll Of Medicine, Rochester · R01 · FY2003 · CA
Topoisomerase I Inhibitors in Leukemia and Solid Tumors
$222,233Mayo Clinic Coll Of Medicine, Rochester · R01 · FY2002 · CA
Role of Erbb3 kinase activity in colorectal tumorigenesis.
$222,180Zhenghe Wang · Case Western Reserve University · R01 · FY2025 · CA
BRCAL AND P21 IN CELL CYCLING
$221,931University Of Pennsylvania · R01 · FY2000 · CA
Project 3: Predictors of sensitivity to immunotherapy and targeted treatments based on real world evidence
$221,756Nikolaus Schultz · Sloan-Kettering Inst Can Research · P01 · FY2025 · CA
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer
$221,727Neeha Zaidi · Johns Hopkins University · K08 · FY2024 · CA
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer
$221,727Neeha Zaidi · Johns Hopkins University · K08 · FY2021 · CA
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer
$221,727Neeha Zaidi · Johns Hopkins University · K08 · FY2022 · CA
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic Cancer
$221,727Neeha Zaidi · Johns Hopkins University · K08 · FY2023 · CA
A synthetic lethal approach for targeting p53 deficient triple negative breast cancer
$221,595Carl G Maki · Rush University Medical Center · R21 · FY2023 · CA
The Roles of a Novel Immune-Checkpoint Receptor Complex in Driving T Cell Dysfunction in Cancer
$221,286Li Lily Wang · Cleveland Clinic Lerner Com-Cwru · R21 · FY2023 · CA
Dietary methionine restriction as a therapeutic strategy for metastatic melanoma
$221,280Isabelle Racine Miousse · University Of Arkansas At Fayetteville · P20 · FY2023 · GM
Novel PTPRD interaction Controlling T cell Responsiveness
$221,250Michael Croft · La Jolla Institute For Immunology · R21 · FY2017 · AI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer
$221,242Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA